New Trends in Topical and Systemic Immunosuppressive Treatment

Handbook of Systemic Autoimmune Diseases

Volumn 5, Issue , 2006, Pages 325-335

  Schneider, Matthias ^a   Fischer Betz, Rebecca ^a   Gensch, Kristina ^a   Iking Konert, Christof ^a   Kuhn, Annegret ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645451513     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(05)05023-3     Document Type: Review

References (68)

1. Aarden L.A., Lakmaker F., and Feltkamp T.E.W. Immunology of DNA. II. The effect of size and structure of the antigen on the Farr assay. J. Immunol. Meth. 10 (1976) 39
2. Alarcón-Segovia D., Tumlin J.A., Furie R.A., et al. The LJP Investigator Consortium. LJP 394 for the prevention of renal flares in patients with systemic lupus erythematosus. Results from a randomised, double-blind, placebo-controlled study. Arthritis Rheum. 48 (2003) 442
3. Anolik J.H., Barnard J., Cappione A., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3580
4. Aringer M., Graninger W., Steiner G., et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3161
5. Assmann T., Homey B., and Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin. Pharmacother. 2 (2001) 1167
6. Assmann T., and Ruzicka T. New immunosuppressive drugs in dermatology (Mycophenolate Mofetil, Tacrolimus): unapproved uses dosages, or indication. Clin. Derm. 20 (2002) 505
7. Bacman D., Tanbajewa A., Megahed M., et al. Topical treatment with tacrolimus in lupus erythematosus tumidus. Hautarzt. 54 (2003) 977
8. Böhm M., Gaubitz M., Luger T.A., et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. Dermatology 207 (2003) 381
9. Bornhovd E., Burgdorf W.H., and Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol. 45 (2001) 736
10. Buyon J.P., Petri M.A., Kim M.Y., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomised trial. Ann. Intern. Med. 142 (2005) 953
11. Chan T.M., Li F.K., Tang C.S., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 350 (2004) 971
12. Chang D.M., Chu S.J., Chen H.C., et al. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. 63 (2004) 1623
13. Chang D.M., Lan J.-L., Lin H.-Y., and Luo S.-F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2924
14. Cheer S.M., and Plosker G.L. Tacrolimus Ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am. J. Clin. Dermatol. 2 (2001) 1
15. Colonna M., Trinchieri G., and Liu Y.-J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5 (2004) 1219
16. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350 (2004) 971
17. De Bandt M., Sibilia J., Le Loet X., et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy, a French national survey. Arthritis Res. Ther. 7 (2005) R545
18. Dostal C., Tesal V., Rychlik I., et al. Effect of 1 year ciclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus, a pilot study. Lupus 7 (1998) 29
19. Druke A., Gambichler T., Altmeyer P., et al. 1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J. Dermatol. Treat. 15 (2004) 63
20. Emlen W., Jarusiripipat P., and Burdick G. A new ELISA for the detection of double-stranded DNA antibodies. J. Immunol. Meth. 132 (1990) 91
21. Furie R.A., Cash J.M., Cronin M.E., et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28 (2001) 257
22. Gensburger D., Kawashima M., Marotte H., et al. Lupus erythematosus with leflunomide, induction or reactivation?. Ann. Rheum. Dis. 64 (2005) 153
23. Ginzler E.M., Buyon J., Dooley M.A., et al. A multicenter study of mycophenolate mofetil vs. intravenous cyclophosphamide as induction therapy for severe lupus nephritis, preliminary results. Arthritis Rheum. 49 (2003) S647
24. Gisondi P., Ellis N.C., and Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int. J. Clin. Pract. 59 (2005) 969
25. Gupta A.K., Adamiak A., and Chow M. Tacrolimus: a review of its use for the management of dermatoses. JEADV 16 (2002) 100
26. Hillmen P., Hall C., Marsh J.C.W., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350 (2004) 552
27. Hollar C.B., and Jorizzo J.L. Topical tacrolimus 0. 1% ointment for refractory skin disease in dermatomyositis: a pilot study. J. Dermatol. Treat. 15 (2004) 35
28. Hughes, G.R.V., D'Cruz, D. (Eds.), 2005. Supplement issue mycophenolate mofetil, an advance in the therapy of autoimmune disease. Lupus 14, S1. The recent advance of mycophenolate mofetil in autoimmune disease is reflected in this review.
29. Iking-Konert C., Stocks S., Weinsberg F., et al. First clinical trials of a new heteropolymer technology agent in healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104. Ann. Rheum. Dis. 63 (2004) 1104
30. Kapp A., Papp K., Bingham A., et al. Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 110 (2002) 277
31. Kanekura T., Yoshii N., Terasaki K., et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br. J. Dermatol. 148 (2003) 353
32. Khandpur, S., Sharma, V.K., Sumanth, K. 2004. Topical immunomodulators in dermatology. J. Postgrad. Med. 50, 131. In this article, the mechanism of action, common indications and most common side effects of topical immunomodulators are summarized.
33. Kreuter A., Gambichler T., Breuckmann F., et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 51 (2004) 407
34. Lampropoulos C.E., Sangle S., Harrison P., et al. Topical tacrolimus therapy of resistant cutaneous lesions in Lupus erythematosus: a possible alternative. Rheumatology 43 (2004) 1383
35. Lauwers B.R., Garot N., Renauld J.-C., et al. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patient. Arthritis Rheum. 43 (2000) 1976
36. Leandro M.J., Edwards J.C., Canbridge G., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2673
37. Liang, M.H., Fortin, P., Schneider, M., et al. 2004. The American College of Rheumatology response criteria for systemic lupus erythematosus. Arthritis Rheum. 50, 3418. ACR developed standardized response criteria are reported and evaluated for the measurement of overall disease activity in SLE.
38. Lindorfer M.A., Hahn C.S., Foley P.L., et al. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1, mechanisms and applications. Immunol. Rev. 183 (2001) 10
39. Linnik M.D., Hu J.Z., Heilbrunn K.R., et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 52 (2005) 1129
40. Llorente L., Richaud-Patin Y., Garcia-Padilla C., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43 (2000) 1790
41. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus, a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580
42. Luger T.A., and Gollnick H. Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis). J. Dtsch. Dermatol. Ges. 3 (2005) 415
43. Luger T.A., Van Leent E.J., Graeber M., et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. 144 (2001) 788
44. Mancuso G., and Berdondini R.M. Topical tacrolimus in the treatment of localized scleroderma. Eur. J. Dermatol. 13 (2003) 590
45. Mrowietz U., Graeber M., Bräutigam M., et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol. 139 (1998) 992
46. Nasr I.S. Topical tacrolimus in dermatology. Clin. Exp. Dermatol. 25 (2000) 250
47. Petri M. High dose Arava in lupus. Arthritis Rheum. 44 (2001) S280
48. Petri M.A., Lahita R.G., van Vollenhoven R.F., et al. Effects of prasterone on corticoid requirements of women with systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 1820
49. Petri M.A., Mease P.J., Merrill J.T., et al. Effects of prasterone on disease activity and symptoms in women with systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 2858
50. Pisoni C.N., Sanchez F.J., Karim Y., et al. Mycophenolate mofetil in systemic lupus erythematosus, efficacy and tolerability in 86 patients. J. Rheum. 32 (2005) 1047
51. Queille-Roussel C., Graeber M., Thursten M., et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 42 (2000) 349
52. Remer C.F., Weisman M.H., and Wallace D.J. Benefits of leflunomide in systemic lupus erythematosus, a pilot observational study. Lupus 10 (2001) 480
53. Ruderman E.M., and Pope R.M. The evolving clinical profile of abatacept (CTLA4-19) a novel costimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 7 (2005) 521
54. Ruzicka T., Assmann T., and Homey B. Tacrolimus: the drug for the turn of the millennium?. Arch. Dermatol. 135 (1999) 574
55. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the costimulatory molecule CD40 ligand. Arthritis Rheum. 52 (2005) 501
56. Starzl T.E., Todo S., Fung J., et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 28 (1989) 1000
57. Stohl W. Systemic lupus erythematosus, a blissless disease of too much BlyS protein. Curr. Opin. Rheum. 14 (2002) 522
58. Swaak A.J.G., Aarden L.A., Statius, VanEps L.W., et al. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum. 22 (1979) 226
59. Tokunaga M., Fujii K., Saito K., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44 (2005) 176
60. Leent E.J., Graber M., Thurston M., et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol. 134 (1998) 805
61. Van Vollenhoven R.F., Engleman E.G., and McGuire J.L. An open study dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 37 (1994) 1305
62. Van Vollenhoven R.F., Engleman E.G., and McGuire J.L. Dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 38 (1995) 1826
63. Walker S.E. Bromocriptine treatment of systemic lupus erythematosus. Lupus 10 (2001) 762
64. Walker S.L., Kirby B., and Chalmers R.J. The effect of topical tacrolimus on severe recalcitrant chronic disoid lupus erythematosus. Br. J. Dermatol. 147 (2002) 405
65. Wong J.M., and Esdaile J.M. Methotrexate in systemic lupus erythematosus. Lupus 14 (2005) 101
66. Wong W., Venetz J.P., Tolkoff-Rubin N., et al. Immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors?. Transplantation 80 (2005) 289
67. Yin Z., Bahtiyar G., Zhang N., et al. IL-10 regulates murine lupus. J. Immunol. 169 (2002) 2148
68. Yoshimasu T., Ohtani T., Sakamoto T., et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur. J. Dermatol. 12 (2002) 50